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Abstract
Background: In clinical practice a diagnosis is based on a combination of clinical history, physical
examination and additional diagnostic tests. At present, studies on diagnostic research often report
the accuracy of tests without taking into account the information already known from history and
examination. Due to this lack of information, together with variations in design and quality of
studies, conventional meta-analyses based on these studies will not show the accuracy of the tests
in real practice. By using individual patient data (IPD) to perform meta-analyses, the accuracy of
tests can be assessed in relation to other patient characteristics and allows the development or
evaluation of diagnostic algorithms for individual patients.
In this study we will examine these potential benefits in four clinical diagnostic problems in the field
of gynaecology, obstetrics and reproductive medicine.
Methods/design: Based on earlier systematic reviews for each of the four clinical problems,
studies are considered for inclusion. The first authors of the included studies will be invited to
participate and share their original data. After assessment of validity and completeness the acquired
datasets are merged. Based on these data, a series of analyses will be performed, including a
systematic comparison of the results of the IPD meta-analysis with those of a conventional meta-
analysis, development of multivariable models for clinical history alone and for the combination of
history, physical examination and relevant diagnostic tests and development of clinical prediction
rules for the individual patients. These will be made accessible for clinicians.
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Discussion: The use of IPD meta-analysis will allow evaluating accuracy of diagnostic tests in
relation to other relevant information. Ultimately, this could increase the efficiency of the
diagnostic work-up, e.g. by reducing the need for invasive tests and/or improving the accuracy of
the diagnostic workup. This study will assess whether these benefits of IPD meta-analysis over
conventional meta-analysis can be exploited and will provide a framework for future IPD meta-
analyses in diagnostic and prognostic research.
Background
Ancient Egyptian medical papyri (1550 BC) already
emphasised diagnosis by physical examination as the cor-
nerstone of the decision to treat or not to treat an ailment
[1]. Today, the clinical assessment of the probability of a
disease comes from a series of implicitly and explicitly
performed tests. In addition to the implicit diagnostic
information from history (risk factors and symptoms)
and clinical examination (signs), many additional diag-
nostic imaging or laboratory tests are available. The accu-
racy of such tests requires to be appropriately assessed
before they can be used in clinical practice.
Studies on primary diagnostic research typically examine
the accuracy of a test isolated from history and clinical
examination or do not adjust for overlap of information
captured by clinical history, physical examination and
additional tests. Such studies and conventional meta-
analyses of their reported results will therefore not show
how useful the test will be in practice [2-4].
In addition to the predominance of isolated, single test
evaluations in published literature, variations in design
and quality of studies on diagnostic topics [5-8] make the
interpretation of test accuracy data difficult [9-12]. Sys-
tematic reviews and meta-analyses, by definition, can not
overcome these difficulties [13]. Apart from intrinsic flaws
in the original studies and methodological challenges in
statistically pooling results [14,15], there is concern about
the generalisability of results of such meta analyses, due to
the invalidity of assumptions about the constancy of accu-
racy measures (sensitivities, specificities, and likelihood
ratios) across different patient groups [16-20].
Due to the limited space in medical journals and the lack
of standard procedures to make original data accessible,
little empirical evidence is available about the influence of
many patient and study characteristics (i.e. patients' selec-
tion criteria, spectrum of disease, frequency of indetermi-
nate test results and of drop outs, and the degree of
blinding) on the estimates of diagnostic performance of
tests [13,21].
Another limitation is the fact that many original reports of
diagnostic and prognostic meta-analyses report data only
in a dichotomous way, since many test results that are
continuous in nature are classified as abnormal or nor-
mal. By doing so, these meta-analyses are based on
reduced information, thus neglecting the potential diag-
nostic information contained in continuous test results.
They possibly give an overestimation of the accuracy by
selection of optimal cut-off values in the original studies
[3,22-24].
As a consequence, it is difficult to make a good assessment
of the generalisability of the accuracy of tests, either in an
isolated situation as well in the context of other tests.
In contrast with conventional meta-analysis of test accu-
racy studies, individual patient data (IPD) meta-analysis
has the potential to establish the value of test combina-
tions. First, in IPD meta-analysis test results can be ana-
lysed taking into account the continuous test results rather
than the dichotomous classification that is generally used
in reports of diagnostic and prognostic tests. The use of
original continuous data instead of the dichotomized
reported test results creates the possibility to detect a
(gradual) relation between test result and disease and it
makes it possible to estimate test accuracy at different cut-
off values. Second, the additional information provided
by diagnostic tests can be examined in light of the diag-
nostic information already known from history and clini-
cal examination, and less expensive or less invasive tests
[16,22,25-28].
Assumptions about invariance of test accuracy across a
range of disease prevalences (prior probabilities) can be
tested. Finally, also the association across patient-level
characteristics or between patient level and study level
characteristics (setting, study design) can be assessed,
without the ecological fallacy problem.
To our knowledge, no IPD meta-analyses of diagnostic or
prognostic research have been conducted so far. In this
paper we describe the outline of a research program to sys-
tematically evaluate the potential benefits of IPD meta-
analyses in the evaluation of diagnostic tests. Thereby, we
selected four clinical problems from gynaecology, obstet-
rics and reproductive medicine that will be used as clinical
cases for this methodological project:BMC Medical Research Methodology 2009, 9:22 http://www.biomedcentral.com/1471-2288/9/22
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1. Diagnosis of endometrial cancer in women with post-
menopausal bleeding (PMB)
2. Prediction of preterm birth
3. Diagnosis of tubal pathology in subfertile women
4. Assessment of ovarian response in women undergoing
in vitro fertilisation (IVF)
The objectives and research methods will be outlined
below, and practical, methodological and clinical issues
that we anticipate to encounter will be discussed.
Objectives of the study
The major goal of this study will be the development of
prediction rules and diagnostic algorithms for individual
patients. We will create these rules and algorithms by per-
forming IPD meta-analysis on the four clinical problems
mentioned above. Within this major goal, we address
both methodological as well as clinical objectives.
Methodological objectives
First, we aim to contribute to the development of a frame-
work for performing IPD meta-analyses and to provide
practical and methodological recommendations on how
to perform an IPD meta-analysis in diagnostic and prog-
nostic research.
Second, we will attempt to gain a better understanding of
sources of heterogeneity between studies and to explore
the role of missing values in this type of meta-analysis.
Finally, we aim to compare IPD analyses with those based
on aggregated data in conventional meta-analyses, to
explore when the IPD approach is beneficial, and when a
conventional approach suffices for reliable and unbiased
estimates of diagnostic/prognostic accuracy.
Clinical objectives
The clinical objective of the project is to create optimal
diagnostic and prognostic strategies, incorporating proba-
bilistic models for the individual patient profile and make
them available to clinicians in ways that allow their prac-
tical integration with clinical practice.
With the help of IPD meta-analysis we aim to re-analyse
the estimates of diagnostic or prognostic accuracy of tests
in their clinical context and for different subgroups and
compare them to estimates resulting from a more conven-
tional meta-analytic approach.
Assuming that taking into account relevant patient and
clinical history characteristics together with physical
examination and several tests, by using probabilistic mod-
els, improves the accuracy and efficiency of the diagnostic
work-up, this probabilistic approach could be used to
improve clinical practice.
In addition, current guidelines for the management for
each of the four clinical examples will be adjusted to
reflect the results of this study and to provide support for
using probabilistic models in the clinical setting.
Clinical examples of diagnostic/prognostic problems
Prediction rules and diagnostic algorithms will be devel-
oped for each of the four clinical problems:
Postmenopausal bleeding
Post-menopausal bleeding (PMB) accounts for a large
proportion of gynaecological consultations in both pri-
mary and secondary care [29]. In most instances, PMB
results from benign causes. However, as endometrial can-
cer is present in 5–10% of PMB patients, further testing to
exclude cancer is mandatory, but there is still controversy
on the best diagnostic strategy. Currently, the first step in
the diagnostic work-up of PMB is transvaginal sonogra-
phy (TVS). There is debate on the value of transvaginal
sonography, which could potentially be replaced by inva-
sive investigations -hysteroscopy with or without biopsy-
in some situations [30,31]. As most original studies
reported the diagnostic accuracy of transvaginal sonogra-
phy in a dichotomous way, they possibly have overesti-
mated the performance of this test [23]. In addition,
information gained by clinical history and physical exam-
ination (e.g. age, parity and diabetes), contains relevant
diagnostic information concerning the presence or
absence of endometrial carcinoma [32], which is not
taken into account in the conventional meta-analysis
[33]. With the individual patient data these problems can
potentially be overcome [34].
Prediction of preterm birth
Preterm birth occurs in 7% of all deliveries – 15.000 cases
per year in the Netherlands – and accounts for 70% of
perinatal mortality and 40% of severe cerebral morbidity
[35]. Many researchers have therefore put effort in strate-
gies to prevent preterm birth [36]. These efforts are
becoming more important, as there is now evidence that
treatment with progesterone is effective in the prevention
of preterm birth in high risk women. Such strategies
always start with the identification of women at risk for
preterm birth [37].
Diagnosis of tubal pathology
In the United States, about 8% of all women between 15
and 44 years are suffering from subfertility [38]. In the
Netherlands, the percentage of couples suffering from
subfertility is estimated to be between 12% and 17%,
depending on the age of the woman [39]. With spermBMC Medical Research Methodology 2009, 9:22 http://www.biomedcentral.com/1471-2288/9/22
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defects and ovulation disorders, tubal disease ranks
among the most frequent causes of subfertility. In tubal
pathology, either one tube or both tubes are occluded,
thus preventing the sperm to reach the oocyte. Prevalence
of tubal disease has been estimated to range between 10–
30%, which implicates that about 2,500 to 7,500 Dutch
women are diagnosed with tubal pathology each year.
Multiple tests for the evaluation of tubal patency exist, of
which the most commonly used are Chlamydia Antibody
Tests (CAT), hysterosalpingography (HSG) and diagnostic
laparoscopy with chromopertubation, the latter often
being considered a gold standard test.
At the moment, there is no consensus on which test
should be initially used in the diagnostic work-up, or on
the most effective and cost-effective sequence of tests.
By using IPD meta-analysis we will integrate patient char-
acteristics and results of diagnostic tests for individual
patients with subfertility and assess various combinations
and sequences of tests.
Assessment of ovarian response in IVF
Around 15.000 IVF/ICSI cycles are performed each year in
the Netherlands. The most important single factor to
determine success is maternal age. Age related decline of
success is largely attributable to a progressive decrease of
oocyte quality and quantity with increasing female age.
Over the past two decades a number of ovarian reserve
tests have been designed and evaluated for their ability to
predict outcome of IVF in terms of oocyte yield and occur-
rence of pregnancy [40]. Many of these tests have become
part of the routine diagnostic procedure in subfertile
patients that will undergo assisted reproductive tech-
niques. Based on these tests couples are counselled on
their pregnancy chances prior to IVF, and individual dose
adjustments are often suggested. However, assessment of
mutual dependence between these tests in conventional
meta-analyses is difficult and many studies report test
accuracy of these continuous tests around an artificial cut-
off level. Moreover, the added value of the tests to female
age has hardly been addressed [41,42].
Methods/Design
General methods
Identification and selection of studies
Previously, systematic reviews of studies on diagnostic
and prognostic test accuracy for each of the four clinical
topics were performed and by means of these reviews we
identified the relevant primary research in these four areas
[30,31,36,37,40,43-47]. For an overview of the amount of
included studies in these meta-analyses see figures 1 to 4.
We will update the performed search strategies to include
studies published up to date. We will perform a computer-
ized search, check references and asks authors of relevant
studies whether they are aware of unpublished or ongoing
studies. Readers of this protocol, who are familiar with
studies performed on these four clinical topics that are not
integrated in the previous performed meta-analyses, are
also invited to approach us.
We aim to include datasets from all studies meeting the
inclusion criteria of the original (updated) reviews. Stud-
ies that have met the inclusion criteria in the meta-analy-
ses on postmenopausal bleeding were prospective studies
that reported on endometrial thickness and in which the
transvaginal ultrasound was performed before tissue
Overview of studies included in the systematic reviews and  meta-analyses on postmenopausal bleeding. Not updated Figure 1
Overview of studies included in the systematic 
reviews and meta-analyses on postmenopausal 
bleeding. Not updated. The number of included studies is 
related to the year of publication.
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Overview of studies included in the systematic reviews and  meta-analyses on preterm birth. Not updated Figure 2
Overview of studies included in the systematic 
reviews and meta-analyses on preterm birth. Not 
updated. The number of included studies is related to the 
year of publication.
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assessment. The selection criteria for the meta-analyses on
preterm birth were studies on asymptomatic or sympto-
matic pregnant women, cervicovaginal fetal fibronectin
testing before 37 weeks' gestation, known gestation at
spontaneous birth and observational cohort design. The
meta-analyses on tubal pathology included studies that
compared CAT or HSG to laparoscopy for tubal pathology
and that described a clear distinction between tubal occlu-
sion and peritubal adhesions. For the ovarian reserve tests
meta-analyses included studies that reported on the asso-
ciation of follicle stimulating hormone (FSH), anti-mulle-
rian hormone (AMH), antral follicle count (AFC), ovarian
volume or clomiphene citrate challenge test (CCCT) with
poor ovarian response or pregnancy after IVF. All meta-
analyses only included studies with sufficient data to con-
struct 2 × 2 tables. Exclusion criteria were a lack of binary
data for constructing the 2 × 2 tables and inadequate study
quality. Study quality was defined as a clear description of
sampling, data collection, study design, blinding, (par-
tial) verification and missing data. Adequate test descrip-
tion and description of either the population or the
reference test was also included in the assessment of study
quality [30,31,36,37,40,43-47].
Including all available studies in our IPD meta-analyses
will maximise our ability to study the factors associated
with heterogeneity in model intercepts and coefficients
and diagnostic odds ratios. We will therefore also consider
studies that have potentially collected relevant data, but
that have been excluded in previous analyses.
Data acquisition
We will approach all authors of the selected original stud-
ies to inform them about this IPD meta-analysis project
and invite them to share their data in this collaborative
project. If they are inclined to participate, they are pro-
vided with a more detailed study proposal, and asked to
send their original datasets. We ask them to send the com-
plete database as to minimise their efforts going through
their dataset to select the appropriate variables. Any data
format is accepted, provided that variables and categories
are adequately labelled within the dataset or with a sepa-
rate data dictionary. We aim to include datasets from all
studies meeting our target variables as described in table
1. Minimal requested data are (anonymous) patient iden-
tifiers, index tests and reference tests (See * in table 1).
Studies in which a substantial part of these variables are
missing are considered to have incomplete data. We will
also ask authors to examine the provisional study list to
identify any additional studies they may be aware of. In
this way also data from studies that have been missed by
our search criteria, or have not been published at all, will
be considered for inclusion.
Quality assessment
We will define study quality of the original studies to a
large extent in the same way as it was described in the sys-
tematic reviews (see above under the heading 'data acqui-
sition'). We will report the study quality according to the
STARD statement [48]. Completeness of datasets in terms
of which diagnostic indicators were assessed and to which
extent data on a particular indicator are complete,
together with, if possible, an assessment of how well the
study execution adhered to the research protocol, will also
be assessed to describe study quality. An attempt will be
made to rank data sets according to their quality.
Quality of the received data will be judged by the assess-
ment of consistency of the data and the published manu-
Overview of studies included in the systematic reviews and  meta-analyses on tubal pathology. Not updated Figure 3
Overview of studies included in the systematic 
reviews and meta-analyses on tubal pathology. Not 
updated. The number of included studies is related to the 
year of publication.
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Overview of studies included in the systematic reviews and  meta-analyses on ovarian response in IVF. Not updated Figure 4
Overview of studies included in the systematic 
reviews and meta-analyses on ovarian response in 
IVF. Not updated. The number of included studies is 
related to the year of publication.
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script. We will also assess reproducibility of the reported
accuracy in the manuscript using the raw data. By request-
ing the original research protocols we will be able to create
an overview of included patients and test sequences,
which might be used to explain the heterogeneity between
included studies. We also will perform thorough data
checks (single variables, simple tables and plots). The
original investigators will be contacted to confirm missing
data or to check values of doubtful validity. In addition to
this, further details during discussions with primary inves-
tigators at a collaborators meeting, may shed light on spe-
cific problems encountered during study execution, and
resolve differences due to the use of different definitions.
Such discussions may give us more precise descriptions of
the test procedures used, and the proficiency of the exam-
iners, if the protocols were unclear on these points.
Unfortunately some data may have to be excluded from
the IPD meta-analyses due to incomplete data or major
inconsistencies with published results. Data are only con-
sidered to be incomplete when a substantial part of the
most relevant variables was not available in the original
study and the original authors are not able to provide the
missing data. We emphasise that a valid diagnostic model
can be derived based on fewer than all available data sets.
General statistical analyses
After the assessment of study and data quality the variable
codes of all the acquired data will be compared between
the original databases. If the variables are compatible the
original data will be merged and a study identification
variable will be added to reflect the stratified nature of the
pooled dataset. Within this database we will create sub-
groups on all relevant issues concerning the clinical prob-
lems (see table 2). For all subgroups we will construct 2 ×
2 tables, comparing the dichotomised test result to the
final disease status. We will then calculate sensitivity and
specificity, and plot the results in a ROC-space. These
summary receiver operating characteristic (SROC) data
and ROC curves will show the differences in the accuracy
of the index tests in comparison to the best available ref-
erence tests between the different subgroups. Differences
in diagnostic performance across subgroups will be
accounted for using interaction effects. Furthermore, we
will look at the distributions of continuous variables in
both diseased and non-diseased patients in various stud-
ies. If these distributions appear to be different between
studies, a correction will be applied using the multiple of
the median as unit for the test result.
Data on continuous test results will allow us to determine
different cut-off values using ROC curves and area under
the curve measurements and show whether the accuracy
of the test was possibly overestimated in the original stud-
ies, reporting artificial cut-off values.
After these exercises we will calculate positive and nega-
tive predicted values for the clinical problems and per-
Table 1: Variables from the original studies to be included in the IPD meta-analyses.
Topics Postmenopausal bleeding Preterm birth Tubal pathology Ovarian response in IVF
Population Postmenopausal bleeding Asymptomatic early pregnancies Subfertility Indication for IVF treatment
Threatened pre-term labour
Patient characteristics -Age -Age -Age -Age
-HRT use -Obstetric history -Fertility history -Fertility history
-BMI -BMI -PID -BMI
-Time since menopause -Multiple pregnancies -Ectopic pregnancy -Previous ART
-Diabetes -Parity -BMI -Smoking
-Hypertension -Diabetes -Pelvic surgery
-Use of anticoagulants
-Previous cancer
-Thyroid dysfunction
Diagnostic tests -TVS* -Blood pressure -CAT* -FSH*
-Hysteroscopy/curettage* -Cervical length measurement* -HSG* -AFC
-Histology of carcinoma* -Fibronectin test* -Laparoscopy* -AMH
Target condition Endometrial carcinoma* Childs condition Tubal pathology* Ovarian response Pregnancy*
Delivery prior to 32 weeks*
Overview of variables that will be requested from the original authors.
Marked variables (*) are the minimal requested variables; studies missing a substantial part of these variables will be excluded.
Abbreviations used: HRT: Hormone Replacement Therapy, TVs: Trans Vaginal Sonography, BMI: Body Mass Index, PID: Pelvic Inflammatory 
Disease, CAT: Chlamydia Antibody Test, HSG: Hysterosalpingography, ART: Assisted Reproductive Therapy, FSH: Follicle Stimulating Hormone, 
AFC: Antral Follicle Count, AMH: Anti Mullerian Hormone.BMC Medical Research Methodology 2009, 9:22 http://www.biomedcentral.com/1471-2288/9/22
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form univariable analyses, using all available
characteristics of clinical history, physical examination
and the several diagnostic tests. The assumption of linear-
ity between predictor and disease state will be evaluated
for continuous variables using both quartile analysis and
smoothed piecewise polynomials (splines) [49].
This will be followed by fitting univariable models. Sub-
sequently, multivariable regression models will be cre-
ated, both for clinical history and examination alone, as
well as for various combinations and sequences of rele-
vant patient characteristics with additional tests. This will
finally lead to the development of the individual diagnos-
tic or prognostic algorithm. We will use imputation strat-
egies that we have applied previously for missing data at
the individual level. For missing data at the study level
(i.e. information not documented in a study), we will also
consider imputation to allow multivariable analyses on
the most complete dataset, although the added value of
such major imputation efforts may be limited and will be
Table 2: Analyses to be performed in the IPD meta-analyses.
Topics Postmenopausal bleeding Preterm birth Tubal pathology Ovarian response in IVF
ROC analysis -TVS* -Cervical length* -Age* -Age*
-CAT* -FSH*
-AFC*
-AMH*
Univariable analyses All relevant patient 
characteristics
All relevant patient 
characteristics
All relevant patient 
characteristics
All relevant patient 
characteristics
Multivariable model patient 
characteristics only
-Age -Age -Age -Age
-HRT use -Obstetric history -Fertility history
-BMI -BMI -PID
-Time since menopause -Multiple pregnancies -Ectopic pregnancy
-Diabetes -Parity -BMI
-Hypertension -Diabetes -Pelvic surgery
-Anticoagulants use -Blood pressure
-Previous cancer
-Thyroid dysfunction
Tests in multivariable 
model with tests
-TVS -Cervical length -CAT -AFC
-Hysteroscopy -Fibronectin test -HSG -FSH
-Laparoscopy -AMH
Subgroup analysis -BMI* -Age* -Age*
-Diabetes -PID -Duration subfertility*
Duration subfertility* -Type subfertility
-Type subfertility -BMI*
-BMI*
-CAT
Diagnostic decision rules:
1. Patient characteristics 
rule
histology if ca > 3%
2. Selective rule TVS if ca > 3% → > 4 mm: 
histology
3. Integrated rule TVS and histology if ca > 
3%
Decision analysis -Patient characteristics -Patient valuations
-Tubal pathology -IVF success
Combined analyses Combination with 
progesterone
Combination with IVF 
outcome
Overview of variables and analyses that will be used, specified for each clinical topic. Marked variables (*) will also be assessed as continuous data.BMC Medical Research Methodology 2009, 9:22 http://www.biomedcentral.com/1471-2288/9/22
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explored in the perspective of IPD meta-analysis [50]. The
multilevel approach will allow for variation in parameter
estimates across studies (random effects). We will explore
whether some of this study level variation can be attrib-
uted to study level characteristics, e.g. quality, design, etc.
Moreover, we will assess efficiency (number of diagnostic
procedures, number of subsequent procedures), and com-
pare this to current clinical practice.
To compare the results of the included studies in the IPD
meta-analysis approach we will also perform a conven-
tional diagnostic meta-analysis for the same set of studies.
As this work has in part already been performed
[30,31,36,37,40,43-47] this will be a repeat of previous
work, in which subtle adjustments to the methodology of
previous meta-analyses will be made.
Model validation
To adjust for overfitting, we plan to use several internal
validation techniques (bootstrap (patient level), leave one
out (study-level)) [51]. We intend to internally validate
the complete analytical process including the imputation
of missing values and that may necessitate the writing of
dedicated programs. We will also apply leave-one-out
approaches, as developed in the context of the modelling
of prognosis of HIV infection [52], by fitting candidate
models on pooled data from all but one of the studies and
testing generalisability on the omitted study. This proce-
dure will be repeated n-1 times, rotating the left out study.
We will use deviance differences to quantify the addi-
tional lack-of-fit when a model is fitted on one data set
and predictions are made on another data set [53]. The
deviance differences will be summed across the test stud-
ies: the best-generalizing model was that with the lowest
total deviance difference. The available data-sets will also
allow us to perform so called external validation. At exter-
nal validation, the performance of the developed model is
validated in a different data-set.
Specific methods for clinical topics
The analyses described above will be assessed for all four
clinical topics. For an outline of the individual assess-
ments of the topics see the following part and table 2.
Postmenopausal bleeding
Data collected will contain patient characteristics and tests
as described in table 1. Final disease status, i.e. the pres-
ence or absence of endometrial cancer, can be diagnosed
with mircocurettage, curettage after dilatation and/or hys-
teroscopy. After univariable analysis we will build a mul-
tivariable model to predict endometrial carcinoma using
the patient characteristics. Age will be defined as the age at
which the first episode of postmenopausal bleeding
occurred. Categorical variables with subdivisions (e.g.
type and management of diabetes) will be dichotomised.
We will develop two multivariable logistic regression
models. The first model will be based on patient charac-
teristics only ("patient characteristics model"). In the sec-
ond model, patient characteristics will be combined with
endometrial thickness as measured with transvaginal
sonography ("patient characteristics and TVS model").
Since it has been reported previously that the accuracy of
endometrial thickness measurement is different in obese
and non-obese women and in diabetic and non-diabetic
women [33], differences in diagnostic performance across
subgroups will be evaluated through interaction terms.
Finally, three different diagnostic decision rules based on
these two models will be explored in terms of diagnostic
efficiency, and compared to current clinical practice (i.e.
transvaginal ultrasound, with histological assessment in
women with endometrial thickness of 5 mm or more).
The three evaluated strategies will be
(1) the "patient characteristics" rule, i.e. probability esti-
mates based on patient characteristics, and invasive diag-
nostics in case the probability of (pre) malignancy is over
3%. In this decision rule TVS is not performed.
(2) "selective" rule, i.e. probability estimates based on
patient characteristics, TVS in case the probability for can-
cer exceeds 3%, and subsequent histological analyses
when the endometrial thickness exceeds 4 mm.
(3) "integrated" rule, i.e. TVS in all patients, with a prob-
ability estimate based on both patient characteristics and
TVS results, completed by endometrial sampling when the
probability of cancer exceeds 3%.
Prediction of preterm birth
Data collected will contain patient characteristics and tests
as described in table 1.
We will use several outcome measures, including the con-
dition of the child. However, for the purpose of the
present study, delivery prior to 32 weeks will be the pri-
mary outcome. We will look at the distribution of several
characteristics, including cervical length. Subsequently,
we will perform receiver-operating characteristic analysis
for cervical length, as well as other continuous tests. We
will build two multivariable models to predict preterm
birth. The first model will be based on patient characteris-
tics only ("patient characteristics model"). In the second
model, patient characteristics will be combined with cer-
vical length and fibronectin. We plan to combine the diag-
nostic data with data from the effectiveness of
progesterone in the prevention of preterm birth, as the lat-
ter agent has found to be effective in the prevention of pre-
term birth in women with a previous preterm deliveryBMC Medical Research Methodology 2009, 9:22 http://www.biomedcentral.com/1471-2288/9/22
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[54]. By doing so, we can assess the efficiency of several
strategies to prevent a preterm birth.
Diagnosis of tubal pathology
Data collected will contain patient characteristics and tests
as described in table 1.
Presence of tubal pathology will be the primary outcome
measure. We will perform all analysis twice. In the first
analysis, tubal pathology will be defined as two-sided
tubal occlusion. In the second analysis, tubal pathology
will be defined as any form of tubal occlusion, be it one-
sided or two-sided. We will perform ROC-analyses for
continuous variables, such as age and CAT. Subsequently,
univariable logistic regression analysis will be performed.
This analysis will continue on an analysis that we have
performed previously [55]. Again, we will develop several
multivariable models. The first model will be based on
patient characteristics only. In a second model, these
patient characteristics will be combined with the Chlamy-
dia Antibody Test measurements. We can also use various
combinations and sequences of patient characteristics and
additional tests. These models will lead to the develop-
ment of the diagnostic algorithm for the individual
patient suffering from tubal pathology. Finally, the data of
the constructed algorithms for tubal pathology will be
combined with data on the prediction of successful IVF-
outcome.
Assessment of ovarian response in IVF
Data collected will contain patient characteristics and tests
as described in table 1.
For the analyses on the ovarian reserve tests we will use
two outcome measures; ovarian response and pregnancy.
The exact definition of these two outcome measures will
depend on the available data and on the outcome of the
discussion at the initiating collaborative work-shop. Vari-
ables considered are shown in table 1. As for the other
clinical examples, ROC-analysis will be performed. We
will develop models for female age alone and for female
age plus AFC. As AFC is at present found to be the best pre-
dictor for IVF outcome, we plan to compare models with
the other tests to a model based on female age plus AFC.
We have previously published a decision analysis in
which we integrated patient valuations of subfertile cou-
ples (incorrect withholding of IVF versus undergoing IVF
without success) and predicted probabilities of IVF-suc-
cess. This analysis revealed a so-called threshold ROC-
curve, which showed the minimal accuracy that an ovar-
ian test (or combination of tests) should have to be of
clinical value [50]. We will repeat the analysis using the
data obtained from the original studies.
Implementation of probabilistic approach in clinical 
practice
We have developed a website with information on the
progress of the project. See http://www.ipd-meta-analy
sis.com/ipd. The website will contain protocols, including
the description of the objectives of each project and pro-
posals for the statistical analyses. Moreover, the diagnostic
algorithms that will be the result of the project will be
available from the website after the studies have been
completed.
The clinical "end products" of these IPD meta-analyses
will be prediction rules for each of the four clinical prob-
lems: women with PMB, women at risk for preterm birth,
women suspected of having tubal pathology, and women
starting with IVF. The results will be made available
through simple scoring chards as well as logistic regres-
sion models. The latter will become accessible through
web applications at which doctors can enter relevant data
of the patient. Furthermore, such prediction rules will be
made available for patients, as we did previously with pre-
diction rules developed for spontaneous pregnancy in
subfertile couples [56]. We will do this with score forms
on paper, website applications and software available
through personal digital assistants.
Collaborative work-shop and definitions
Workshops will be organised with all investigators of the
included studies. In addition to discussing the IPD-meta-
analysis project in general, as well as the practical, meth-
odological and data-related aspects of each original study,
these meetings are also important to build trust. During
these workshops, we will discuss and refine the study pro-
tocol, examine patient characteristics and information
from diagnostic tests that are to be analysed, the data
checking procedures and the main analyses to be per-
formed. Criteria for classifying test results, including
results of reference tests, as positive or negative will also
be discussed, taking into account that the exact nature of
tests and procedures will differ between studies and cen-
tres. We will also propose a timetable and a publication
policy, including a list of anticipated publications, with a
collaborative group authorship for these publications, to
be discussed and agreed upon by all collaborating
authors.
Publication policy
The results from the IPD meta-analysis will be presented
at a collaborators meeting. Any subsequent articles on the
results of the meta-analysis will be published under the
name of the collaborative group. It will also be circulated
to the collaborators for comments, amendments and
approval before finally being submitted. In the case of any
disagreement, the following fundamental principle will
be applied; the report should provide the meta-analysisBMC Medical Research Methodology 2009, 9:22 http://www.biomedcentral.com/1471-2288/9/22
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results, presenting all of the available evidence, but will
not include any interpretations of the data, except those
that are unanimously decided upon by all collaborators.
Any collaborating group is free to withdraw its data at any
stage.
Discussion
Although it is at present stage not possible to exactly antic-
ipate on the clinical and methodological results from the
planned steps in each of the four clinical topics, we expect
to have the following knowledge available at the end of
the project:
Methodological knowledge:
￿ Differences between conventional meta-analyses
with summary estimates of sensitivities, specificities
and ROC-curves, and IPD meta-analyses.
￿ Knowledge of quality of reporting on individual
studies
￿ Knowledge of completeness of data and ways to deal
with missing values
￿ Knowledge of differences and similarities in distribu-
tions of parameters between studies
Clinical knowledge:
￿ Prediction models and diagnostic models obtained
with IPD meta-analyses and the relative performance
in comparison to aggregate meta-analyses
￿ Estimates of accuracy and calibration of the predic-
tion models and diagnostic models
￿ Integration of the diagnostic and prognostic knowl-
edge with knowledge of therapeutic effectiveness
Increased efficiency of the diagnostic work-up by making
optimal use of the patient characteristics combined with
the results of the diagnostic tests, will probably decline the
need of invasive tests and contributes to improved patient
care. With help of the results of the four clinical problems,
we can then assess the potential value of IPD meta-analy-
sis in diagnostic and prognostic models, compared to con-
ventional diagnostic meta-analysis.
From the experiences in the present proposal, we will pro-
vide recommendations on how to perform IPD meta-
analysis in prognostic and diagnostic research.
A final step in the work-plan is to provide these data
through the internet. The progress of the project can be
followed on http://www.ipd-meta-analysis.com/ipd.
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